BenzingaOctober 15, 2026 at 3:05 AM NY12 Days Ago
Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was observed in lesions not directly injected with KB113, consistent with
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
